Invesco
ADMS

Invesco’s Adamas Pharmaceuticals ADMS Stock Holding History

Invesco’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-2,108,442
Closed -$18M – 3886
2018
Q4 		$18M Buy
2,108,442
+29,448
+1% +$383K 0.01% 1192
2018
Q3 		$41.6M Buy
2,078,994
+124,438
+6% +$2.92M 0.01% 926
2018
Q2 		$50.5M Buy
1,954,556
+161,884
+9% +$4.48M 0.02% 839
2018
Q1 		$42.8M Buy
1,792,672
+81,481
+5% +$2.57M 0.02% 804
2017
Q4 		$58M Buy
+1,711,191
New +$47.8M 0.02% 703
2017
Q1 		– Sell
-11,211
Closed -$189K – 3774
2016
Q4 		$189K Sell
11,211
-63
-0.6% -$974 ﹤0.01% 3568
2016
Q3 		$185K Buy
+11,274
New +$171K ﹤0.01% 3548
2016
Q2 		– Sell
-13,710
Closed -$199K – 3742
2016
Q1 		$199K Sell
13,710
-101,340
-88% -$1.71M ﹤0.01% 3562
2015
Q4 		$3.26M Buy
115,050
+919
+0.8% +$15.5K ﹤0.01% 2212
2015
Q3 		$1.91M Buy
114,131
+72,969
+177% +$1.66M ﹤0.01% 2535
2015
Q2 		$1.08M Buy
+41,162
New +$801K ﹤0.01% 3024

Other funds holding ADMS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

Invesco's ADMS Position: Q1 2019 in Review

Invesco sold out of Adamas Pharmaceuticals (ADMS) in Q1 2019, closing a stake of 2,108,442 shares — an estimated $18M sold.

Invesco first reported a position in ADMS in Q2 2015 and held it in 11 quarters. The position peaked at $58M in Q4 2017. 99 funds tracked by Wall St. Rank hold ADMS as of Q1 2019.

  • Invesco reported no remaining Adamas Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Invesco sold 2,108,442 Adamas Pharmaceuticals shares in Q1 2019, an estimated $18M.
  • Invesco first reported a position in Adamas Pharmaceuticals in Q2 2015 and held it in 11 quarters.
  • Invesco's Adamas Pharmaceuticals position peaked at $58M in Q4 2017.
  • 99 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q1 2019.

Based on Invesco's 13F filing for Q1 2019, filed 15 May 2019.